Fitness Pro Superhuman Troy performs a SuperHuman back workout to build width using the Balloon Method. Fox News poll spells bad news for Donald Trump Officers surround building after finding Brown ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dr. Andrew Huberman demonstrates the McGill Method. Dacora Motors introduces American-made luxury car Lady Gaga abruptly stops Mayhem Ball show mid-performance after dancer falls off stage in ...

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company. Several stocks on the market offer investors the opportunity to capitalize on the rapidly ...

Please provide your email address to receive an email when new articles are posted on . Educating children about juvenile idiopathic arthritis and asking them to teach it back can improve ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

These are direct-prediction models trained from scratch on small, heavily augmented datasets—not few-shot prompting. ARC remains the canonical target; broader leaderboard context and rules (e.g., ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...